Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care

British Journal of Clinical Pharmacology
Tomoyuki MizunoAlexander A Vinks

Abstract

Providing maximal therapeutic efficacy without toxicity is a universal goal of rational drug therapy. However, substantial between-patient variability in drug response often impedes such successful treatments and brings the necessity of tailoring drug dose to individual needs for more precise therapy. In many cases plenty of patient characteristics, such as body size, genetic makeup and environmental factors, need to be taken into consideration to find the optimal dose in clinical practice. A pharmacokinetics and pharmacodynamics (PK/PD) model-informed approach offers integration of various patient information to provide an expectation of drug response and derive practical dose estimates to support clinicians' dosing decisions. Such an approach was pioneered in the late 1970s, but its broad clinical acceptance and implementation have been hampered by the lack of widespread computer technology, including user-friendly software tools. This has significantly changed in recent years. With the advent of electronic health records (EHRs) and the ubiquity of user-friendly software tools, we now experience a convergence of clinical information, pharmacogenetics, systems pharmacology and pharmacometrics, and technology. Advanced pharmaco...Continue Reading

References

Sep 1, 1979·Clinical Pharmacology and Therapeutics·L B SheinerV V Marathe
Apr 5, 1984·The New England Journal of Medicine·N L LetvinD G Nathan
Apr 1, 1997·Clinical Pharmacology and Therapeutics·G M FerronW J Jusko
Feb 19, 1998·The New England Journal of Medicine·W E EvansC H Pui
Apr 19, 2000·Clinical Transplantation·B D KahanC T Van Buren
Oct 5, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R B Ettenger, E M Grimm
Jan 15, 2004·British Journal of Anaesthesia·N J BouwmeesterN H G Holford
Jul 29, 2005·Pediatric Transplantation·Leonard C Hymes, Barry L Warshaw
Sep 26, 2006·British Journal of Clinical Pharmacology·Chantaratsamon DansirikulStephen B Duffull
Aug 30, 2008·British Journal of Anaesthesia·K J S AnandUNKNOWN NEOPAIN Trial Investigators Group
Aug 5, 2009·Clinical Pharmacokinetics·Catherijne A J KnibbeDick Tibboel
Aug 8, 2009·British Journal of Clinical Pharmacology·Zheng JiaoMing-kang Zhong
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa R TreviñoMary V Relling
Feb 16, 2010·Journal of Clinical Pharmacology·Michael Neely, Roger Jelliffe
Apr 10, 2010·Haematologica·Jeffrey D LebensburgerDerek A Persons
Jan 29, 2011·Clinical Pharmacology and Therapeutics·M V Relling, T E Klein
Feb 15, 2011·Pharmacogenetics and Genomics·Torben S MikkelsenRuss B Altman
Mar 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Torben S MikkelsenWilliam E Evans
Jan 4, 2012·Paediatric Anaesthesia·Nick H G HolfordBrian J Anderson
May 30, 2012·Computer Methods and Programs in Biomedicine·Joakim NybergAndrew C Hooker
Sep 6, 2012·Clinical Pharmacology and Therapeutics·L J Lesko, S Schmidt
Dec 1, 2012·Clinical Pharmacokinetics·Aline FuchsNicolas Widmer
Dec 13, 2012·Blood·Laura B RamseyMary V Relling
Apr 17, 2013·Clinical Pharmacology and Therapeutics·A R ShuldinerChristopher G Chute
May 15, 2013·Therapeutic Drug Monitoring·Jeffrey R ScottAlexander A Vinks
Jun 14, 2013·Cancer Chemotherapy and Pharmacology·Jennifer L PauleyMary V Relling
Jan 1, 2012·CPT: Pharmacometrics & Systems Pharmacology·K WuR R Bies
Feb 6, 2014·Clinical Pharmacokinetics·Elke H J KrekelsCatherijne A J Knibbe
Sep 10, 2014·JAMA : the Journal of the American Medical Association·Barbara P YawnJoylene John-Sowah
Jan 31, 2015·The New England Journal of Medicine·Francis S Collins, Harold Varmus

❮ Previous
Next ❯

Citations

Oct 14, 2020·Expert Opinion on Drug Metabolism & Toxicology·Matthijs W van HoogdalemTomoyuki Mizuno
Mar 13, 2021·Frontiers in Pediatrics·Alan AbdullaMatthijs de Hoog
Aug 31, 2021·Current Reviews in Clinical and Experimental Pharmacology·Ehab S El Desoky
Nov 4, 2021·Expert Opinion on Drug Metabolism & Toxicology·Denise TürkThorsten Lehr

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.